Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial
• Survival rates for Wilms tumour were similar whatever the reason to be stage III. • Radiotherapy avoidance in selected stage III WT may not alter survival. • Tumours deemed ‘inoperable’ at diagnosis do not need radiotherapy if pathological stage I/II.
Gespeichert in:
| Autor*in: |
Irtan, Sabine [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
7 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells - Han, Xiaobing ELSEVIER, 2021, journal of the European Society for Therapeutic Radiology and Oncology, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:131 ; year:2019 ; pages:1-7 ; extent:7 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.radonc.2018.10.026 |
|---|
| Katalog-ID: |
ELV045821070 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV045821070 | ||
| 003 | DE-627 | ||
| 005 | 20230624120408.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191021s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.radonc.2018.10.026 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000523.pica |
| 035 | |a (DE-627)ELV045821070 | ||
| 035 | |a (ELSEVIER)S0167-8140(18)33550-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |a 540 |q VZ |
| 100 | 1 | |a Irtan, Sabine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial |
| 264 | 1 | |c 2019 | |
| 300 | |a 7 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Survival rates for Wilms tumour were similar whatever the reason to be stage III. • Radiotherapy avoidance in selected stage III WT may not alter survival. • Tumours deemed ‘inoperable’ at diagnosis do not need radiotherapy if pathological stage I/II. | ||
| 650 | 7 | |a Wilms tumour |2 Elsevier | |
| 650 | 7 | |a Stage III |2 Elsevier | |
| 650 | 7 | |a Radiotherapy |2 Elsevier | |
| 700 | 1 | |a Messahel, Boo |4 oth | |
| 700 | 1 | |a Moroz, Veronica |4 oth | |
| 700 | 1 | |a Taylor, Roger E. |4 oth | |
| 700 | 1 | |a Grundy, Richard |4 oth | |
| 700 | 1 | |a Kelsey, Anna |4 oth | |
| 700 | 1 | |a Vujanic, Gordan |4 oth | |
| 700 | 1 | |a Pritchard-Jones, Kathy |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Han, Xiaobing ELSEVIER |t Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |d 2021 |d journal of the European Society for Therapeutic Radiology and Oncology |g Amsterdam [u.a.] |w (DE-627)ELV00004122X |
| 773 | 1 | 8 | |g volume:131 |g year:2019 |g pages:1-7 |g extent:7 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.radonc.2018.10.026 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 131 |j 2019 |h 1-7 |g 7 | ||
| author_variant |
s i si |
|---|---|
| matchkey_str |
irtansabinemessahelboomorozveronicataylo:2019----:ucmsfoaalsisaeiadnprbeimtmut |
| hierarchy_sort_str |
2019 |
| publishDate |
2019 |
| allfields |
10.1016/j.radonc.2018.10.026 doi GBV00000000000523.pica (DE-627)ELV045821070 (ELSEVIER)S0167-8140(18)33550-3 DE-627 ger DE-627 rakwb eng 570 540 VZ Irtan, Sabine verfasserin aut Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial 2019 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Survival rates for Wilms tumour were similar whatever the reason to be stage III. • Radiotherapy avoidance in selected stage III WT may not alter survival. • Tumours deemed ‘inoperable’ at diagnosis do not need radiotherapy if pathological stage I/II. Wilms tumour Elsevier Stage III Elsevier Radiotherapy Elsevier Messahel, Boo oth Moroz, Veronica oth Taylor, Roger E. oth Grundy, Richard oth Kelsey, Anna oth Vujanic, Gordan oth Pritchard-Jones, Kathy oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:131 year:2019 pages:1-7 extent:7 https://doi.org/10.1016/j.radonc.2018.10.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 131 2019 1-7 7 |
| spelling |
10.1016/j.radonc.2018.10.026 doi GBV00000000000523.pica (DE-627)ELV045821070 (ELSEVIER)S0167-8140(18)33550-3 DE-627 ger DE-627 rakwb eng 570 540 VZ Irtan, Sabine verfasserin aut Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial 2019 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Survival rates for Wilms tumour were similar whatever the reason to be stage III. • Radiotherapy avoidance in selected stage III WT may not alter survival. • Tumours deemed ‘inoperable’ at diagnosis do not need radiotherapy if pathological stage I/II. Wilms tumour Elsevier Stage III Elsevier Radiotherapy Elsevier Messahel, Boo oth Moroz, Veronica oth Taylor, Roger E. oth Grundy, Richard oth Kelsey, Anna oth Vujanic, Gordan oth Pritchard-Jones, Kathy oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:131 year:2019 pages:1-7 extent:7 https://doi.org/10.1016/j.radonc.2018.10.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 131 2019 1-7 7 |
| allfields_unstemmed |
10.1016/j.radonc.2018.10.026 doi GBV00000000000523.pica (DE-627)ELV045821070 (ELSEVIER)S0167-8140(18)33550-3 DE-627 ger DE-627 rakwb eng 570 540 VZ Irtan, Sabine verfasserin aut Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial 2019 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Survival rates for Wilms tumour were similar whatever the reason to be stage III. • Radiotherapy avoidance in selected stage III WT may not alter survival. • Tumours deemed ‘inoperable’ at diagnosis do not need radiotherapy if pathological stage I/II. Wilms tumour Elsevier Stage III Elsevier Radiotherapy Elsevier Messahel, Boo oth Moroz, Veronica oth Taylor, Roger E. oth Grundy, Richard oth Kelsey, Anna oth Vujanic, Gordan oth Pritchard-Jones, Kathy oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:131 year:2019 pages:1-7 extent:7 https://doi.org/10.1016/j.radonc.2018.10.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 131 2019 1-7 7 |
| allfieldsGer |
10.1016/j.radonc.2018.10.026 doi GBV00000000000523.pica (DE-627)ELV045821070 (ELSEVIER)S0167-8140(18)33550-3 DE-627 ger DE-627 rakwb eng 570 540 VZ Irtan, Sabine verfasserin aut Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial 2019 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Survival rates for Wilms tumour were similar whatever the reason to be stage III. • Radiotherapy avoidance in selected stage III WT may not alter survival. • Tumours deemed ‘inoperable’ at diagnosis do not need radiotherapy if pathological stage I/II. Wilms tumour Elsevier Stage III Elsevier Radiotherapy Elsevier Messahel, Boo oth Moroz, Veronica oth Taylor, Roger E. oth Grundy, Richard oth Kelsey, Anna oth Vujanic, Gordan oth Pritchard-Jones, Kathy oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:131 year:2019 pages:1-7 extent:7 https://doi.org/10.1016/j.radonc.2018.10.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 131 2019 1-7 7 |
| allfieldsSound |
10.1016/j.radonc.2018.10.026 doi GBV00000000000523.pica (DE-627)ELV045821070 (ELSEVIER)S0167-8140(18)33550-3 DE-627 ger DE-627 rakwb eng 570 540 VZ Irtan, Sabine verfasserin aut Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial 2019 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Survival rates for Wilms tumour were similar whatever the reason to be stage III. • Radiotherapy avoidance in selected stage III WT may not alter survival. • Tumours deemed ‘inoperable’ at diagnosis do not need radiotherapy if pathological stage I/II. Wilms tumour Elsevier Stage III Elsevier Radiotherapy Elsevier Messahel, Boo oth Moroz, Veronica oth Taylor, Roger E. oth Grundy, Richard oth Kelsey, Anna oth Vujanic, Gordan oth Pritchard-Jones, Kathy oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:131 year:2019 pages:1-7 extent:7 https://doi.org/10.1016/j.radonc.2018.10.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 131 2019 1-7 7 |
| language |
English |
| source |
Enthalten in Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells Amsterdam [u.a.] volume:131 year:2019 pages:1-7 extent:7 |
| sourceStr |
Enthalten in Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells Amsterdam [u.a.] volume:131 year:2019 pages:1-7 extent:7 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Wilms tumour Stage III Radiotherapy |
| dewey-raw |
570 |
| isfreeaccess_bool |
false |
| container_title |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| authorswithroles_txt_mv |
Irtan, Sabine @@aut@@ Messahel, Boo @@oth@@ Moroz, Veronica @@oth@@ Taylor, Roger E. @@oth@@ Grundy, Richard @@oth@@ Kelsey, Anna @@oth@@ Vujanic, Gordan @@oth@@ Pritchard-Jones, Kathy @@oth@@ |
| publishDateDaySort_date |
2019-01-01T00:00:00Z |
| hierarchy_top_id |
ELV00004122X |
| dewey-sort |
3570 |
| id |
ELV045821070 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV045821070</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624120408.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.radonc.2018.10.026</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000523.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV045821070</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-8140(18)33550-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Irtan, Sabine</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Survival rates for Wilms tumour were similar whatever the reason to be stage III. • Radiotherapy avoidance in selected stage III WT may not alter survival. • Tumours deemed ‘inoperable’ at diagnosis do not need radiotherapy if pathological stage I/II.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Wilms tumour</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Stage III</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Radiotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Messahel, Boo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moroz, Veronica</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Taylor, Roger E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grundy, Richard</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kelsey, Anna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vujanic, Gordan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pritchard-Jones, Kathy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Han, Xiaobing ELSEVIER</subfield><subfield code="t">Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells</subfield><subfield code="d">2021</subfield><subfield code="d">journal of the European Society for Therapeutic Radiology and Oncology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00004122X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:131</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:1-7</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.radonc.2018.10.026</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">131</subfield><subfield code="j">2019</subfield><subfield code="h">1-7</subfield><subfield code="g">7</subfield></datafield></record></collection>
|
| author |
Irtan, Sabine |
| spellingShingle |
Irtan, Sabine ddc 570 Elsevier Wilms tumour Elsevier Stage III Elsevier Radiotherapy Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial |
| authorStr |
Irtan, Sabine |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV00004122X |
| format |
electronic Article |
| dewey-ones |
570 - Life sciences; biology 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
570 540 VZ Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial Wilms tumour Elsevier Stage III Elsevier Radiotherapy Elsevier |
| topic |
ddc 570 Elsevier Wilms tumour Elsevier Stage III Elsevier Radiotherapy |
| topic_unstemmed |
ddc 570 Elsevier Wilms tumour Elsevier Stage III Elsevier Radiotherapy |
| topic_browse |
ddc 570 Elsevier Wilms tumour Elsevier Stage III Elsevier Radiotherapy |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
b m bm v m vm r e t re ret r g rg a k ak g v gv k p j kpj |
| hierarchy_parent_title |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| hierarchy_parent_id |
ELV00004122X |
| dewey-tens |
570 - Life sciences; biology 540 - Chemistry |
| hierarchy_top_title |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV00004122X |
| title |
Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial |
| ctrlnum |
(DE-627)ELV045821070 (ELSEVIER)S0167-8140(18)33550-3 |
| title_full |
Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial |
| author_sort |
Irtan, Sabine |
| journal |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| journalStr |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
zzz |
| container_start_page |
1 |
| author_browse |
Irtan, Sabine |
| container_volume |
131 |
| physical |
7 |
| class |
570 540 VZ |
| format_se |
Elektronische Aufsätze |
| author-letter |
Irtan, Sabine |
| doi_str_mv |
10.1016/j.radonc.2018.10.026 |
| dewey-full |
570 540 |
| title_sort |
outcomes of non-anaplastic stage iii and ‘inoperable’ wilms tumour treated in the ukw3 trial |
| title_auth |
Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial |
| abstract |
• Survival rates for Wilms tumour were similar whatever the reason to be stage III. • Radiotherapy avoidance in selected stage III WT may not alter survival. • Tumours deemed ‘inoperable’ at diagnosis do not need radiotherapy if pathological stage I/II. |
| abstractGer |
• Survival rates for Wilms tumour were similar whatever the reason to be stage III. • Radiotherapy avoidance in selected stage III WT may not alter survival. • Tumours deemed ‘inoperable’ at diagnosis do not need radiotherapy if pathological stage I/II. |
| abstract_unstemmed |
• Survival rates for Wilms tumour were similar whatever the reason to be stage III. • Radiotherapy avoidance in selected stage III WT may not alter survival. • Tumours deemed ‘inoperable’ at diagnosis do not need radiotherapy if pathological stage I/II. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial |
| url |
https://doi.org/10.1016/j.radonc.2018.10.026 |
| remote_bool |
true |
| author2 |
Messahel, Boo Moroz, Veronica Taylor, Roger E. Grundy, Richard Kelsey, Anna Vujanic, Gordan Pritchard-Jones, Kathy |
| author2Str |
Messahel, Boo Moroz, Veronica Taylor, Roger E. Grundy, Richard Kelsey, Anna Vujanic, Gordan Pritchard-Jones, Kathy |
| ppnlink |
ELV00004122X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.radonc.2018.10.026 |
| up_date |
2024-07-06T18:34:43.406Z |
| _version_ |
1803855733360427008 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV045821070</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624120408.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.radonc.2018.10.026</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000523.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV045821070</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-8140(18)33550-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Irtan, Sabine</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Outcomes of non-anaplastic stage III and ‘inoperable’ Wilms tumour treated in the UKW3 trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Survival rates for Wilms tumour were similar whatever the reason to be stage III. • Radiotherapy avoidance in selected stage III WT may not alter survival. • Tumours deemed ‘inoperable’ at diagnosis do not need radiotherapy if pathological stage I/II.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Wilms tumour</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Stage III</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Radiotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Messahel, Boo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moroz, Veronica</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Taylor, Roger E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grundy, Richard</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kelsey, Anna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vujanic, Gordan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pritchard-Jones, Kathy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Han, Xiaobing ELSEVIER</subfield><subfield code="t">Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells</subfield><subfield code="d">2021</subfield><subfield code="d">journal of the European Society for Therapeutic Radiology and Oncology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00004122X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:131</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:1-7</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.radonc.2018.10.026</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">131</subfield><subfield code="j">2019</subfield><subfield code="h">1-7</subfield><subfield code="g">7</subfield></datafield></record></collection>
|
| score |
7.4003096 |